INS and Insulin resistance: In assessing the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), which takes into account fasting insulin and glucose levels and is a marker for health outcomes related to metabolic syndrome, we found no difference in this metric at the end of the intervention between the responder or non-responder group and placebo (unpaired t-test, p-value = 0.16 and 0.58, respectively).